These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16353381)

  • 1. PTH (1-34): a novel anabolic drug for the treatment of osteoporosis.
    Holick MF
    South Med J; 2005 Nov; 98(11):1114-7. PubMed ID: 16353381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parathyroid hormone as an anabolic skeletal therapy.
    Rubin MR; Bilezikian JP
    Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of PTH in the treatment of osteoporosis.
    Borba VZ; Mañas NC
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
    Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
    Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of parathyroid hormone in the treatment of osteoporosis.
    Girotra M; Rubin MR; Bilezikian JP
    Rev Endocr Metab Disord; 2006 Jun; 7(1-2):113-21. PubMed ID: 17043762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of osteoporosis with PTH].
    Takeuchi Y
    Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anabolic agents: a new chapter in the management of osteoporosis.
    Khan AW; Khan A
    J Obstet Gynaecol Can; 2006 Feb; 28(2):136-41. PubMed ID: 16643716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination anabolic and antiresorptive therapy for osteoporosis.
    Cusano NE; Bilezikian JP
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anabolic agents: what is beyond osteoporosis?
    Liu Y; Levack AE; Marty E; Or O; Samuels BP; Redko M; Lane JM
    Osteoporos Int; 2018 May; 29(5):1009-1022. PubMed ID: 29627891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone.
    Anastasilakis AD; Savvides M; Polyzos SA; Georgopoulos C; Delaroudis S
    J Bone Miner Metab; 2010; 28(1):108-10. PubMed ID: 19578808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.
    Bilezikian JP; Rubin MR
    Curr Osteoporos Rep; 2006 Mar; 4(1):5-13. PubMed ID: 16527002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.
    Dempster DW; Zhou H; Recker RR; Brown JP; Recknor CP; Lewiecki EM; Miller PD; Rao SD; Kendler DL; Lindsay R; Krege JH; Alam J; Taylor KA; Janos B; Ruff VA
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1353-63. PubMed ID: 26859106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anabolic therapy for osteoporosis.
    Bilezikian JP
    Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anabolic therapy for osteoporosis: parathyroid hormone.
    Cosman F
    Curr Osteoporos Rep; 2005 Dec; 3(4):143-9. PubMed ID: 16303114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.